The MYL2 gene is associated with a form of cardiomyopathy known as familial hypertrophic cardiomyopathy type 10 (HCM 10). This condition is characterized by the thickening of the heart muscle, which can lead to various complications, including heart failure, arrhythmias, and sudden cardiac death. The MYL2 gene encodes for the regulatory light chain of myosin, a protein essential for heart muscle contraction. Mutations in the MYL2 gene disrupt this process, leading to the development of HCM.
In the United Arab Emirates, DNA Labs UAE offers a genetic test specifically designed to identify mutations in the MYL2 gene associated with familial hypertrophic cardiomyopathy type 10. This test is crucial for individuals with a family history of HCM or those exhibiting symptoms related to heart muscle dysfunction, as it can confirm the diagnosis and facilitate appropriate management and treatment strategies.
The cost of the MYL2 Gene Cardiomyopathy Familial Hypertrophic Type 10 Genetic Test at DNA Labs UAE is 4400 AED. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect the presence of any genetic alterations in the MYL2 gene. The results of this test can provide valuable information for affected individuals and their families, including the risk of developing HCM, implications for family planning, and the need for regular cardiac monitoring or intervention.
The ACTC1 gene plays a crucial role in the development and function of heart muscle. Mutations in this gene are associated with familial hypertrophic cardiomyopathy type 11 (HCM11), a genetic disorder characterized by the thickening of the heart's ventricular walls. This condition can lead to various complications, including heart failure, arrhythmias, and sudden cardiac death.
To diagnose this condition, DNA Labs UAE offers a genetic test specifically targeting the ACTC1 gene. This test is designed to identify mutations within the gene that are linked to familial hypertrophic cardiomyopathy. Early detection through genetic testing is crucial for managing the condition, allowing for timely intervention and management strategies to mitigate the risk of complications.
The cost of the ACTC1 Gene Cardiomyopathy familial hypertrophic type 11 Genetic Test at DNA Labs UAE is 4400 AED. This test is a valuable resource for individuals with a family history of cardiomyopathy, providing them with critical information about their genetic predisposition to the condition. With this knowledge, affected individuals and their healthcare providers can make informed decisions regarding surveillance, lifestyle adjustments, and potential treatments to improve heart health and quality of life.
The CSRP3 gene plays a critical role in the structure and function of the heart muscle. Mutations in the CSRP3 gene are linked to a condition known as familial hypertrophic cardiomyopathy (HCM) type 12. This condition is characterized by the thickening of the heart muscle, which can lead to heart failure and other serious cardiovascular issues. Early detection and management are crucial to improving outcomes for individuals with this condition.
DNA Labs UAE offers a specialized genetic test designed to identify mutations in the CSRP3 gene associated with familial hypertrophic cardiomyopathy type 12. This test is an important tool for individuals with a family history of cardiomyopathy or those exhibiting symptoms related to the condition. By analyzing a person's genetic material, the test can confirm the presence of specific mutations in the CSRP3 gene that are known to cause the disease.
The cost of the CSRP3 gene cardiomyopathy familial hypertrophic type 12 genetic test at DNA Labs UAE is 4400 AED. The test provides valuable information that can guide clinical decisions, including surveillance and management strategies for affected individuals and their families. It is a critical step towards personalized medicine, allowing for targeted interventions that can significantly improve the quality of life for those with familial hypertrophic cardiomyopathy type 12.
The "MYOZ2 Gene Cardiomyopathy Familial Hypertrophic Type 16 Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, aimed at detecting mutations in the MYOZ2 gene, which have been associated with Familial Hypertrophic Cardiomyopathy (FHC) Type 16. This condition is a form of heart disease that is inherited in an autosomal dominant pattern, characterized by the thickening of the heart's muscle tissue (hypertrophy), which can lead to various cardiac issues, including heart failure, arrhythmias, and sudden cardiac death. The test plays a crucial role in early detection and management of the condition, enabling healthcare providers to tailor treatment plans and advise on lifestyle adjustments or interventions that may mitigate the progression of the disease or prevent its onset in at-risk individuals. The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the significant value it provides in terms of personal and family health management. DNA Labs UAE, by offering this test, plays a pivotal role in advancing personalized medicine and providing critical insights into inherited cardiac conditions.
The JPH2 Gene Cardiomyopathy Familial Hypertrophic Type 17 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the JPH2 gene, which are implicated in the development of Familial Hypertrophic Cardiomyopathy (FHC) Type 17. This condition is a form of heart disease characterized by the thickening of the heart muscle, potentially leading to heart failure and sudden cardiac death. Early detection through genetic testing can be crucial for managing the condition, guiding treatment options, and informing at-risk family members about their genetic predisposition.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient's DNA to detect specific mutations in the JPH2 gene. The process is meticulous, ensuring high accuracy and reliability in the results. The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the analysis and the specialized expertise required to interpret the results.
For individuals with a family history of cardiomyopathy or symptoms indicative of the condition, this genetic test provides a vital tool for early intervention and personalized care planning. By understanding one's genetic makeup, patients and healthcare providers can work together to monitor heart health more closely and take preventive measures to mitigate the risks associated with Familial Hypertrophic Cardiomyopathy Type 17.
The CALR3 Gene Cardiomyopathy Familial Hypertrophic Type 19 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the CALR3 gene that are associated with Familial Hypertrophic Cardiomyopathy (FHC) Type 19. This condition is a form of heart disease that is inherited in an autosomal dominant pattern, characterized by the thickening of the heart's muscle tissue which can lead to heart failure and other complications.
The test is particularly important for individuals with a family history of cardiomyopathy or those exhibiting symptoms related to heart muscle disorders, as it can provide crucial information for diagnosis, treatment planning, and risk assessment for family members. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for specific genetic mutations in the CALR3 gene known to contribute to this condition.
At DNA Labs UAE, the cost for the CALR3 Gene Cardiomyopathy Familial Hypertrophic Type 19 Genetic Test is set at 4400 AED. This investment includes the cost of sample collection, genetic analysis, and a comprehensive report that outlines the findings. The results from this test can empower patients and their healthcare providers with the knowledge needed to make informed decisions about management strategies, including lifestyle adjustments, medical surveillance, and potential treatment options to mitigate the impact of the condition.
The TNNT2 gene, associated with familial hypertrophic cardiomyopathy type 2, plays a critical role in the cardiovascular system's function. Mutations in this gene are linked to the development of this form of cardiomyopathy, a condition characterized by the thickening of the heart muscle, which can lead to heart failure and other complications. The genetic test for TNNT2 gene mutations is a crucial tool for diagnosing this condition, enabling early intervention and personalized treatment plans.
DNA Labs UAE offers a comprehensive genetic test for the TNNT2 gene to identify mutations related to familial hypertrophic cardiomyopathy type 2. This test is an essential resource for individuals with a family history of cardiomyopathy, as it can provide valuable insights into their risk of developing the condition. By detecting mutations in the TNNT2 gene, the test can help guide clinical decisions, including monitoring and management strategies to mitigate the impact of the disease.
The cost of the TNNT2 gene cardiomyopathy familial hypertrophic type 2 genetic test at DNA Labs UAE is 4400 AED. This investment in health allows individuals and families to take proactive steps in managing and understanding their cardiovascular health, potentially saving lives through early detection and intervention.
The "TPM1 Gene Cardiomyopathy Familial Hypertrophic Type 3 Genetic Test" is a specific diagnostic tool used to identify mutations in the TPM1 gene, which are linked to Familial Hypertrophic Cardiomyopathy Type 3 (FHCM3). This condition is a form of heart disease characterized by the thickening of the heart muscle, which can lead to various complications, including heart failure, arrhythmias, and sudden cardiac death. The TPM1 gene plays a crucial role in the contractile function of heart muscle cells, and mutations in this gene can disrupt this function, leading to the development of cardiomyopathy.
The test is performed at DNA Labs UAE, a state-of-the-art facility known for its advanced genetic testing capabilities. The cost of the test is 4400 AED, making it an investment in personal health for those with a family history of cardiomyopathy or individuals displaying symptoms associated with the condition. By identifying the genetic mutation early, patients can benefit from tailored management strategies aimed at mitigating the progression of the disease and improving quality of life. This test is especially important for families affected by this condition, as it can provide crucial information for the management and potential prevention of the disease in at-risk family members.
The MYBPC3 gene plays a critical role in the structure and function of the heart muscle. Mutations in this gene are a common cause of familial hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle, which can lead to heart failure and sudden cardiac death. Familial hypertrophic cardiomyopathy type 4 specifically refers to the subtype linked to mutations in the MYBPC3 gene.
The genetic test for MYBPC3-associated familial hypertrophic cardiomyopathy type 4 is a vital diagnostic tool. It involves analyzing the patient's DNA to identify mutations in the MYBPC3 gene that are known to cause the condition. This test is crucial not only for diagnosing affected individuals but also for identifying at-risk family members who may benefit from regular cardiac monitoring or preventive treatments.
DNA Labs UAE offers this specialized genetic test, providing a reliable means of diagnosing MYBPC3 gene cardiomyopathy. The test is priced at 4400 AED and is conducted in their state-of-the-art facilities, ensuring accuracy and confidentiality. By opting for this test, individuals and families can gain essential insights into their genetic health, paving the way for informed medical and lifestyle decisions to manage or mitigate the risks associated with familial hypertrophic cardiomyopathy type 4.
The PRKAG2 gene plays a crucial role in the heart's energy metabolism, and mutations in this gene can lead to familial hypertrophic cardiomyopathy type 6 (HCM6). This condition is characterized by the thickening of the heart muscle, which can lead to heart failure and other complications. Early detection and management are vital for improving patient outcomes.
DNA Labs UAE offers a specialized genetic test designed to identify mutations in the PRKAG2 gene associated with familial hypertrophic cardiomyopathy type 6. This test is a valuable tool for individuals with a family history of cardiomyopathy, or those exhibiting symptoms related to heart muscle dysfunction, as it can confirm the diagnosis and aid in the development of a tailored management plan.
The test cost is set at 4400 AED, reflecting the comprehensive analysis and the specialized technology employed to ensure accurate results. Upon opting for this test at DNA Labs UAE, patients can expect a detailed report that not only highlights the presence of any mutations in the PRKAG2 gene but also provides insights that are critical for healthcare providers in planning the most effective treatment strategies.
